TheraCryf (LSE:TCF) FCF Margin % : -321.21% (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is TheraCryf FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. TheraCryf's Free Cash Flow for the six months ended in Sep. 2023 was £-1.27 Mil. TheraCryf's Revenue for the six months ended in Sep. 2023 was £0.40 Mil. Therefore, TheraCryf's FCF Margin % for the quarter that ended in Sep. 2023 was -321.21%.

As of today, TheraCryf's current FCF Yield % is -109.86%.

The historical rank and industry rank for TheraCryf's FCF Margin % or its related term are showing as below:

LSE:TCF' s FCF Margin % Range Over the Past 10 Years
Min: -1510.82 Med: -1222.38 Max: -420.17
Current: -420.17

During the past 11 years, the highest FCF Margin % of TheraCryf was -420.17%. The lowest was -1510.82%. And the median was -1222.38%.

LSE:TCF's FCF Margin % is ranked worse than
64.66% of 1044 companies
in the Biotechnology industry
Industry Median: -146.375 vs LSE:TCF: -420.17

TheraCryf FCF Margin % Historical Data

The historical data trend for TheraCryf's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf FCF Margin % Chart

TheraCryf Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

-1,510.82

-933.94

TheraCryf Semi-Annual Data
	Mar13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-508.82	-321.21

Competitive Comparison of TheraCryf's FCF Margin %

For the Biotechnology subindustry, TheraCryf's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TheraCryf's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TheraCryf's FCF Margin % distribution charts can be found below:

* The bar in red indicates where TheraCryf's FCF Margin % falls into.

TheraCryf FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

TheraCryf's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-4.128	/	0.442
	=	-933.94 %

TheraCryf's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-1.272	/	0.396
	=	-321.21 %

TheraCryf FCF Margin % Related Terms

Thank you for viewing the detailed overview of TheraCryf's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

TheraCryf (LSE:TCF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (LSE:TCF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

8EV:Germany

Address

Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG

Website

https://www.evgen.com

Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.